Court Vacated FDA Regulatory Classification of AXIOFILL

A federal judge ruled that the agency acted arbitrarily in its classification of the tissue-based product.

Updated on Sept. 23, 2026 in Healthcare

Bold flat-color editorial illustration depicting a stylized glass vial containing a segmented biological scaffold matrix, symbolic of regulatory classification. — The U.S. District Court for the Northern District of Georgia has vacated the FDA’s decision to classify the tissue product AXIOFILL as a biological product. AI Illustration. Upload story photo >

Live Poll

Should regulatory agencies be required to explain why they classify similar medical products differently?

The U.S. District Court for the Northern District of Georgia has vacated the FDA’s decision to classify AXIOFILL as a biological product rather than a medical device. The court found that the agency’s determination was arbitrary and remanded the case for further consideration.

Why it matters

The ruling suggests the FDA failed to properly apply its minimal-manipulation regulation, which the court stated should focus on how tissue functions in the recipient rather than the donor. This decision forces the agency to reevaluate its regulatory stance on the product, which first launched in 2022.

AXIOFILL was originally launched in 2022. The product has been subject to FDA scrutiny regarding whether it qualifies as a Section 361 human cell, tissue, and cellular and tissue-based product (HCT/P).

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.

U.S. District Court for the Northern District of Georgia

This federal court holds jurisdiction over cases within the northern region of Georgia and presides over legal disputes involving federal regulatory actions.

The details

The court determined the FDA incorrectly interpreted regulations by focusing on the placental disc's function in the donor rather than its utility for reconstruction or repair in the recipient. Additionally, the judge found the FDA failed to explain why AXIOFILL faced different classification standards than similar products currently on the market.

AXIOFILL entered the market in 2022.
The U.S. District Court for the Northern District of Georgia issued its ruling on September 23, 2026.

Market Landscape

This ruling challenges the FDA's oversight of tissue-based products and underscores a tension between regulators and manufacturers over product classification. By forcing a reevaluation, the court has introduced new uncertainty for companies operating within the complex landscape of biological product regulation.

While the court order requires the FDA to reconsider its classification, the immediate availability of the product remains subject to the agency's subsequent actions. Patients and healthcare providers should monitor future regulatory updates to see if this change affects the supply or status of the product.

The takeaway

This case highlights the importance of precise regulatory interpretation when classifying complex medical products. Stakeholders in the medical device and biological sectors should remain alert to how judicial challenges can reshape market entry requirements and administrative oversight.